Rallybio has appointed Christine Nash, MBA and Hui Liu, Ph.D. to its Board of Directors.
“Christine’s commercial and product launch experience in rare diseases and Hui’s industry experience in business development and finance will be an asset to our Board as Rallybio continues to advance its current product portfolio and bring additional candidates into our pipeline,” said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybio.
In addition, Tim Shannon, M.D. notified the company that he will resign from the Board, effective at Rallybio’s 2022 annual meeting of shareholders.